A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Carcinoma, Non-Small-Cell Lung|Triple Negative Breast Cancer
Interventions: DRUG: Datopotamab Deruxtecan (Dato-DXd)
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo